Cargando…

Management of secondary hyperparathyroidism: practice patterns and outcomes of cinacalcet treatment with or without active vitamin D in Austria and Switzerland – the observational TRANSIT Study

Secondary hyperparathyroidism is a complex disorder requiring an individualized multicomponent treatment approach. This study was conducted to identify treatment combinations used in clinical practice in Austria and Switzerland and the potential to control this disorder. A total of 333 adult hemodia...

Descripción completa

Detalles Bibliográficos
Autores principales: Pronai, Wolfgang, Rosenkranz, Alexander R., Bock, Andreas, Klauser-Braun, Renate, Jäger, Christine, Pendl, Gunther, Hemetsberger, Margit, Lhotta, Karl
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Vienna 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5429358/
https://www.ncbi.nlm.nih.gov/pubmed/28091752
http://dx.doi.org/10.1007/s00508-016-1153-z
_version_ 1783235997512761344
author Pronai, Wolfgang
Rosenkranz, Alexander R.
Bock, Andreas
Klauser-Braun, Renate
Jäger, Christine
Pendl, Gunther
Hemetsberger, Margit
Lhotta, Karl
author_facet Pronai, Wolfgang
Rosenkranz, Alexander R.
Bock, Andreas
Klauser-Braun, Renate
Jäger, Christine
Pendl, Gunther
Hemetsberger, Margit
Lhotta, Karl
author_sort Pronai, Wolfgang
collection PubMed
description Secondary hyperparathyroidism is a complex disorder requiring an individualized multicomponent treatment approach. This study was conducted to identify treatment combinations used in clinical practice in Austria and Switzerland and the potential to control this disorder. A total of 333 adult hemodialysis and peritoneal dialysis patients were analyzed. All patients received conventional care prior to initiation of a cinacalcet-based regimen. During the study, treatment components, e.g. cinacalcet, active vitamin D analogues and phosphate binders, were adapted to individual patient requirements and treatment dynamics were documented. Overall, the mean intact parathyroid hormone (iPTH) increased from 64.2 pmol/l to 79.6 pmol/l under conventional therapy and decreased after cinacalcet initiation to 44.0 pmol/l after 12 months (mean decrease between baseline and 12 months −45%). Calcium remained within the normal range throughout the study and phosphorus ranged around the upper limit of normal. The Kidney Disease: Improving Global Outcomes (KDIGO) target achievement for iPTH increased from 44.5% of patients at baseline to 65.7% at 12 months, corrected calcium from 58.9% to 51.9% and phosphorus from 18.4% to 24.4%. On average, approximately 30% of patients adapted their regimen from one observation period to the next. The reasons for changing a given regimen were to attain or maintain any of the bone mineral markers within recommended targets and to avoid developments to extreme values. Some regional differences in practice patterns were identified. No new safety signals emerged. In conclusion, cinacalcet appears to be a necessary treatment component to achieve recommended targets. The detailed composition of the treatment mix should be adapted to patient requirements and reassessed on a regular basis. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi: 10.1007/s00508-016-1153-z) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5429358
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Springer Vienna
record_format MEDLINE/PubMed
spelling pubmed-54293582017-05-30 Management of secondary hyperparathyroidism: practice patterns and outcomes of cinacalcet treatment with or without active vitamin D in Austria and Switzerland – the observational TRANSIT Study Pronai, Wolfgang Rosenkranz, Alexander R. Bock, Andreas Klauser-Braun, Renate Jäger, Christine Pendl, Gunther Hemetsberger, Margit Lhotta, Karl Wien Klin Wochenschr Original Article Secondary hyperparathyroidism is a complex disorder requiring an individualized multicomponent treatment approach. This study was conducted to identify treatment combinations used in clinical practice in Austria and Switzerland and the potential to control this disorder. A total of 333 adult hemodialysis and peritoneal dialysis patients were analyzed. All patients received conventional care prior to initiation of a cinacalcet-based regimen. During the study, treatment components, e.g. cinacalcet, active vitamin D analogues and phosphate binders, were adapted to individual patient requirements and treatment dynamics were documented. Overall, the mean intact parathyroid hormone (iPTH) increased from 64.2 pmol/l to 79.6 pmol/l under conventional therapy and decreased after cinacalcet initiation to 44.0 pmol/l after 12 months (mean decrease between baseline and 12 months −45%). Calcium remained within the normal range throughout the study and phosphorus ranged around the upper limit of normal. The Kidney Disease: Improving Global Outcomes (KDIGO) target achievement for iPTH increased from 44.5% of patients at baseline to 65.7% at 12 months, corrected calcium from 58.9% to 51.9% and phosphorus from 18.4% to 24.4%. On average, approximately 30% of patients adapted their regimen from one observation period to the next. The reasons for changing a given regimen were to attain or maintain any of the bone mineral markers within recommended targets and to avoid developments to extreme values. Some regional differences in practice patterns were identified. No new safety signals emerged. In conclusion, cinacalcet appears to be a necessary treatment component to achieve recommended targets. The detailed composition of the treatment mix should be adapted to patient requirements and reassessed on a regular basis. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi: 10.1007/s00508-016-1153-z) contains supplementary material, which is available to authorized users. Springer Vienna 2017-01-13 2017 /pmc/articles/PMC5429358/ /pubmed/28091752 http://dx.doi.org/10.1007/s00508-016-1153-z Text en © The Author(s) 2016 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Original Article
Pronai, Wolfgang
Rosenkranz, Alexander R.
Bock, Andreas
Klauser-Braun, Renate
Jäger, Christine
Pendl, Gunther
Hemetsberger, Margit
Lhotta, Karl
Management of secondary hyperparathyroidism: practice patterns and outcomes of cinacalcet treatment with or without active vitamin D in Austria and Switzerland – the observational TRANSIT Study
title Management of secondary hyperparathyroidism: practice patterns and outcomes of cinacalcet treatment with or without active vitamin D in Austria and Switzerland – the observational TRANSIT Study
title_full Management of secondary hyperparathyroidism: practice patterns and outcomes of cinacalcet treatment with or without active vitamin D in Austria and Switzerland – the observational TRANSIT Study
title_fullStr Management of secondary hyperparathyroidism: practice patterns and outcomes of cinacalcet treatment with or without active vitamin D in Austria and Switzerland – the observational TRANSIT Study
title_full_unstemmed Management of secondary hyperparathyroidism: practice patterns and outcomes of cinacalcet treatment with or without active vitamin D in Austria and Switzerland – the observational TRANSIT Study
title_short Management of secondary hyperparathyroidism: practice patterns and outcomes of cinacalcet treatment with or without active vitamin D in Austria and Switzerland – the observational TRANSIT Study
title_sort management of secondary hyperparathyroidism: practice patterns and outcomes of cinacalcet treatment with or without active vitamin d in austria and switzerland – the observational transit study
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5429358/
https://www.ncbi.nlm.nih.gov/pubmed/28091752
http://dx.doi.org/10.1007/s00508-016-1153-z
work_keys_str_mv AT pronaiwolfgang managementofsecondaryhyperparathyroidismpracticepatternsandoutcomesofcinacalcettreatmentwithorwithoutactivevitamindinaustriaandswitzerlandtheobservationaltransitstudy
AT rosenkranzalexanderr managementofsecondaryhyperparathyroidismpracticepatternsandoutcomesofcinacalcettreatmentwithorwithoutactivevitamindinaustriaandswitzerlandtheobservationaltransitstudy
AT bockandreas managementofsecondaryhyperparathyroidismpracticepatternsandoutcomesofcinacalcettreatmentwithorwithoutactivevitamindinaustriaandswitzerlandtheobservationaltransitstudy
AT klauserbraunrenate managementofsecondaryhyperparathyroidismpracticepatternsandoutcomesofcinacalcettreatmentwithorwithoutactivevitamindinaustriaandswitzerlandtheobservationaltransitstudy
AT jagerchristine managementofsecondaryhyperparathyroidismpracticepatternsandoutcomesofcinacalcettreatmentwithorwithoutactivevitamindinaustriaandswitzerlandtheobservationaltransitstudy
AT pendlgunther managementofsecondaryhyperparathyroidismpracticepatternsandoutcomesofcinacalcettreatmentwithorwithoutactivevitamindinaustriaandswitzerlandtheobservationaltransitstudy
AT hemetsbergermargit managementofsecondaryhyperparathyroidismpracticepatternsandoutcomesofcinacalcettreatmentwithorwithoutactivevitamindinaustriaandswitzerlandtheobservationaltransitstudy
AT lhottakarl managementofsecondaryhyperparathyroidismpracticepatternsandoutcomesofcinacalcettreatmentwithorwithoutactivevitamindinaustriaandswitzerlandtheobservationaltransitstudy